INTRODUCTION
The mitotic checkpoint (also known as the spindle assembly checkpoint) delays the irreversible transition into anaphase until kinetochores on all chromosomes successfully attach to spindle microtubules. Each unattached kinetochore produces an inhibitory signal(s) that blocks ubiquitination of cyclin B and securin by inhibiting Cdc20, the preanaphase activator of the E3 ubiquitin ligase, the anaphase-promoting complex or cyclosome (APC/C) (reviewed in Lara-Gonzalez et al., 2012; Peters, 2006) . Anaphase onset is triggered by silencing the checkpoint-derived inhibitor and the subsequent degradation of cyclin B and securin. Critical components of the mitotic checkpoint include Bub1, Bub3, Mad1, Mad2, Mad3 (known as BubR1 outside of yeast), and Mps1 (Hoyt et al., 1991; Li and Murray, 1991; Weiss and Winey, 1996) .
Mad2 is an essential mitotic checkpoint protein that has been shown to directly bind to Cdc20 (Fang et al., 1998) . Structural studies have revealed that Mad2 undergoes a major conformational change (from an open form to a closed form) when it binds to Cdc20 or Mad1 (Luo et al., 2000 (Luo et al., , 2002 (Luo et al., , 2004 Mapelli et al., 2007; Sironi et al., 2001 Sironi et al., , 2002 . In vivo and in vitro fluorescence recovery after photobleaching has led to a model in which open Mad2 is converted to a closed form by recruitment to a stably bound Mad1/Mad2 complex at each unattached kinetochore (Shah et al., 2004; Vink et al., 2006) . This second molecule of Mad2 then quickly cycles on and off unattached kinetochores (De Antoni et al., 2005; Mapelli et al., 2006; Nezi et al., 2006; Shah et al., 2004; Vink et al., 2006) . In vitro reconstitution has established that unattached kinetochores with stably bound Mad1 serve as Mad2 templates to catalyze the production of a diffusible Cdc20 inhibitor (Kulukian et al., 2009 ).
BubR1 has also been shown to associate with Cdc20 (Wu et al., 2000) and can inhibit Cdc20 activation of APC/C either alone (Tang et al., 2001) or in combination with Mad2 (Fang, 2002; Kulukian et al., 2009; Lara-Gonzalez et al., 2011) . Two Cdc20 binding domains have been identified in BubR1: one within the N-terminal Mad3 homology domain and a second at an internal site (Davenport et al., 2006) . Mad2 can enhance BubR1 association with Cdc20 (Davenport et al., 2006; Kulukian et al., 2009 ), but the mechanistic contribution(s) to mitotic checkpoint signaling of the two Cdc20 binding domains in BubR1 remains to be established.
Attempts have been made to identify the mitotic checkpoint inhibitor produced by unattached kinetochores (Chao et al., 2012; Kulukian et al., 2009; Nilsson et al., 2008; Sudakin et al., 2001) . While BubR1, Bub3, and Mad2 have all been found to be complexed with Cdc20 during mitotic checkpoint-mediated arrest, there are major discrepancies in the reported level of Mad2 in the inhibitory complex, spanning from equimolar (Chao et al., 2012; Sudakin et al., 2001 ) to negligible (Nilsson et al., 2008 ) levels compared to Cdc20. Correspondingly, multiple models have been put forward for how APC/C Cdc20 is inhibited. One proposal, based on recent evidence in budding yeast, is that the function of Mad3 (i.e., BubR1) is to promote the inhibition of Cdc20 by Mad2 (Lau and Murray, 2012 ). An alternative model for Cdc20 inhibition relies on cooperative binding of Mad2 and Mad3. Evidence for this model comes from a crystal structure of a fission yeast mutant of Mad2 locked in the closed conformation and complexed with portions of Mad3 and Cdc20. Consistent with this latter model, activity of APC/C Cdc20 has been proposed to be influenced by the sequestration of Cdc20's N-terminal APC/C recognition motifs by Mad2 (Chao et al., 2012; Izawa and Pines, 2012) . Lastly, Mad3/BubR1 may act as a pseudosubstrate inhibitor that competes with substrates for Cdc20 binding in a KEN-box-dependent manner (Burton and Solomon, 2007) . In all of the proposed models, it remains unclear how a single unattached kinetochore can act to generate global inhibition of APC/C Cdc20 activity. Using a combination of purified components and cultured cells, we now identify two sequential, interlocking catalytic steps in the production of the mitotic checkpoint inhibitor in which BubR1, not Mad2, blocks the activity of APC/C Cdc20 . In an initial catalytic step, the Mad1/Mad2 complex acts locally at unattached kinetochores to catalyze the production of closed Mad2 bound to Cdc20. Subsequently, closed Mad2 then functions catalytically as a diffusible loader for generating BubR1 binding to a previously inaccessible site in Cdc20. This produces Cdc20 bound to BubR1 as the functional mitotic checkpoint-derived inhibitor that selectively blocks ubiquitination of cyclin B and securin by APC/C Cdc20 . Figure 1D ). The BubR1 N-terminal-mediated mitotic checkpoint arrest was dependent on Mad2, as it was completely eliminated by small interfering RNA (siRNA)-mediated reduction in Mad2 (Figure 1E) . In contrast, replacement of endogenous BubR1 with variants deleted in the Cdc20 binding site within the Mad3 homology domain was unable to mediate checkpoint signaling in both unperturbed mitosis ( Figures 1C and S1D ) and nocodazole-treated cells ( Figure 1D ). This effect did not depend on whether the BubR1 fragments contained (BubR1 357-1050 ) or lacked (BubR1 357-700 ) the BubR1 kinase domain. Full-length BubR1 mediated nocodazole-induced mitotic arrest longer than BubR1 variants with only the N-terminal Cdc20 binding site, consistent with a possible role of the internal Cdc20 binding site in maintaining chronic mitotic checkpoint signaling.
RESULTS

Inhibition of APC/C
To determine how BubR1 generated a mitotic checkpoint inhibitor together with Mad2, full-length recombinant BubR1 and BubR1 fragments containing either Cdc20 binding domain were expressed, purified (Figures 1F and S1E) , and incubated with Cdc20 along with Bub3 in the presence or absence of Mad2. Inactive APC/C was added and incubated, and the APC/C was subsequently recovered (with an antibody to Cdc27). Finally, cyclin B was added along with E1, the E2 UbcH10, and ubiquitin. APC/C Cdc20 ubiquitination activity was then measured by the increase of multiubiquitinated cyclin B or by the reduction of unubiquitinated cyclin B (Figures S1F and S1G). While full-length wild-type Mad2 alone produced no inhibition of Cdc20's ability to activate APC/C ( Figure S1G ), addition of Bub3 and full-length BubR1 (hereafter BubR1 FL ) along with Cdc20 significantly reduced subsequent APC/Cmediated cyclin B ubiquitination in a dose-dependent manner (Figures S1G, top: lanes 3-6, and S1H, red triangles).
Synergistic inhibition of Cdc20 activation of APC/C was produced by coaddition of BubR1 FL -Bub3 and Mad2 (Figures S1G, top: lanes 11-14, and S1H, blue squares). Assay of Bub3 and a BubR1 variant containing only BubR1's internal Cdc20 binding site (BubR1 , to be referred to hereafter as BubR1 C ) produced a level of inhibition of cyclin B ubiquitination similar to that of a comparable amount of Bub3-BubR1 FL ; however, in the absence of the Mad3-homology region Cdc20 binding site, inhibition was not enhanced by coincubation with Mad2 (Figures S1G, bottom, and S1J). By contrast, BubR1 1-477 (carrying the Mad3 homology region Cdc20 binding domain and to be referred to hereafter as BubR1 N ) had no APC/C Cdc20 inhibitory activity when complexed with Bub3 (Figures S1G, middle: lanes 3-6, and S1I, red triangles), but inhibition was strongly enhanced by addition of an equivalent amount of Mad2 (Figures S1G, middle: lanes 11-14 and 1I, blue squares), which again had no inhibitory activity by itself. Moreover, BubR1 N -Bub3 almost completely inhibited already active APC/C Cdc20 when Mad2 was present ( Figure 1G ).
In contrast, BubR1 C -Bub3 produced minimal APC/C Cdc20 inhibition regardless of the presence of Mad2 ( Figures 1G and 1H) . Thus, the N-terminal, but not the internal, Cdc20 binding domain of BubR1 can mediate Mad2-dependent inhibition of APC/ C Cdc20 , reproducing the in vivo situation ( Figures 1C and 1D) . , we compared inhibition produced by wildtype Mad2, which exists in an open conformation that only slowly and spontaneously converts to a closed form (Yang et al., 2008) , with two Mad2 mutants: closed Mad2 (Mad2 L13A ) (Yang et al., 2007) and open Mad2 (Mad2 DC ) (Luo et al., 2000) ( Figure S2A ).
While closed Mad2 L13A alone (Figures S2D and S2E) had no APC/C inhibitory activity when used at equal stoichiometry with Cdc20, it was much more potent than wild-type Mad2 in promoting BubR1 N -mediated APC/C inhibition, producing comparable inhibition at concentrations five times lower than needed
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Mad2 Catalytically Produces BubR1-Cdc20 Inhibitor (Figures 2A and S2B ).
In light of our evidence for catalytic production of a Mad2-Cdc20 inhibitor in the presence of unattached kinetochores containing the Mad1/Mad2 complex (Kulukian et al., 2009) , we tested if addition of closed Mad2-the proposed product of immobilized Mad1-Mad2 at kinetochores (De Antoni et al., 2005; Kulukian et al., 2009; Luo et al., 2002) -1x 1x 1x 1x 1x 1x 1x 1x 1x 1x --.2x .5x 1x .2x .5x 1x --.2x .5x 1x .2x .5x 1x , the level of Mad2 bound to the produced APC/ C Cdc20 complex was lower than that of BubR1 N ( Figure 2E ).
Mad2 Enables BubR1
Binding to APC/C Cdc20 without Necessarily Remaining Bound While a consensus has emerged that the initiating event in mitotic checkpoint signaling is production of Mad2-Cdc20 by unattached kinetochores, widely divergent levels of Mad2 have been reported (Kulukian et al., 2009; Nilsson et al., 2008; Sudakin et al., 2001; Westhorpe et al., 2011) or predicted (Chao et al., 2012) in the mitotic checkpoint complexes, leaving the molecular identity of the checkpoint-produced inhibitor of APC/C Cdc20 a central unresolved question. Moreover, although Mad2-stimulated BubR1 N -Cdc20 binding was increased at higher Mad2 levels ( Figure S2F ), the level of Mad2 bound to APC/ C Cdc20 in the final complex was lower than the level of BubR1 N ( Figure 2E ). Consistent with this, immunopurified Cdc20 molecules from nocodazole-arrested mitotic cells were associated with 3-fold more BubR1 than Mad2 ( Figures S2G and S2H ), suggesting dissociation of Mad2 from Cdc20 after enabling initial binding of BubR1 N to Cdc20. To determine if continued Mad2-Cdc20 association is required for maintaining a BubR1 association with APC/C Cdc20 ,
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Mad2 Catalytically Produces BubR1-Cdc20 Inhibitor we created a Mad2 mutant (hereafter Mad2 HRV ) that can be removed from an initial APC/C Cdc20 complex through cleavage by the sequence-specific HRV 3C (human rhinovirus 3C) protease (Cordingley et al., 1990 ) ( Figure 3A ). Upon incubation with HRV 3C protease, the 24 kDa Mad2 HRV was cleaved into 15 kDa and 9 kDa fragments ( Figure 3B ). The digested Mad2 HRV fragments were nonfunctional as inhibitors of APC/C Cdc20 (Figure S3) . APC/C was incubated with Cdc20, BubR1 N , and Bub3 (at 1:1:1 stoichiometries) and a 5-fold excess of Mad2 HRV , a concentration that produces similar levels of BubR1 N and Mad2 bound to Cdc20 ( Figure 3D ). Protease treatment reduced Mad2 HRV bound to APC/C Cdc20 by 80% ( Figures 3C and 3D) , with most of the C-terminal Mad2 HRV fragment (containing residues required for binding to Cdc20 and Mad3, the yeast homolog of BubR1; Chao et al., 2012) dissociated from APC/ C Cdc20 ( Figure 3C , lanes 3 and 4). Importantly, the level of BubR1 N bound to Cdc20 remained almost unchanged, despite a >5-fold reduction of Cdc20-bound Mad2 ( Figures 3C  and 3D ). Taken together, these findings demonstrate that Mad2 stimulates the initial BubR1 N -Cdc20 interaction but is dispensable for maintaining this association. and Cdc20, APC/C was affinity purified to remove unbound components. Following incubation with or without HRV 3C protease, dissociated components were washed away, and APC/C was peptide eluted from beads and analyzed for associated components by immunoblotting. The supernatant from the protease digestion mixture was collected and analyzed for release of the digested Mad2 did not affect the amount of Mad2 retained ( Figures 3G  and 3H ). Additionally, since Mad2 association with APC/C was completely dependent on the presence of Cdc20 (Figure 3I ), the Mad2 remaining in the BubR1-depleted complexes must be bound to Cdc20, and the Mad2-Cdc20 interaction does not depend on the BubR1-Cdc20 interaction.
To address the individual function of Mad2 and BubR1 N in inhibiting activity of APC/C Cdc20 , the inhibitor-bound APC/C complex containing BubR1 N-HRV or Mad2 HRV was incubated with the HRV 3C protease. Nearly quantitative digestion of Mad2 did not significantly alter APC/C inhibition ( Figures  4A-4D ). Digestion of BubR1 N-HRV , on the other hand, reduced APC/C inhibition by 70% ( Figures 4C, lanes 7 and 8, and 4D , right set), with the residual 30% inhibition of APC/C attributable to the incomplete digestion of the BubR1 N-HRV ( Figures 3F and 3G) . Similarly, digestion of BubR1 FL-HRV (full-length BubR1 that contains the recognition sequence for HRV 3C protease) bound to APC/C Cdc20 significantly reduced APC/C inhibition ( Figure S4 ). Figure 5A ). Addition of the auxin derivative IAA to cells arrested in mitosis induced rapid destruction of both AID-tagged BubR1 and Mad2 with time for 50% degradation (t 1/2 ) of 15 and 30 min, respectively, while proteins associated with either remained stable ( Figures 5B and S5A) . Suppression of endogenous BubR1 or Mad2 by transfection of appropriate siRNAs and doxycycline induction led to their replacement with GFP-AID-BubR1 or Mad2-AID-YFP ( Figure 5D ). Cdc20 has been shown to undergo autoubiquitination and turnover during mitosis (King et al., 2007; Nilsson et al., 2008; Pan and Chen, 2004; Reddy et al., 2007; Varetti et al., 2011) , leading to disassembly of the Cdc20-associated checkpoint inhibitor(s). Since the rapid turnover of checkpoint inhibitor(s) in vivo would preclude identifying whether Mad2 or BubR1 is the final inhibitor(s) of APC/C Cdc20 , we codepleted p31 comet to stabilize Cdc20 inhibitor(s) (Jia et al., 2011; Mapelli et al., 2006; Reddy et al., 2007; Teichner et al., 2011; Varetti et al., 2011; Westhorpe et al., 2011) . Following checkpoint activation and IAA-induced degradation of Mad2-AID-YFP or GFP-AIDBubR1, the duration of mitotic checkpoint-mediated arrest was determined by time-lapse microscopy. Addition of IAA to mitotically arrested Mad2-AID-YFP-expressing cells induced destruction of 90% of Mad2-AID-YFP within 60 min, but, remarkably, all cells remained arrested in mitosis ( Figure 5E, red) . Indeed, after Mad2-AID-YFP degradation, 60% of cells sustained a mitotic arrest for >6 hr, similar to the duration observed in cells not treated with IAA and in which Mad2-AID-YFP remained stable ( Figure 5E , green). Mad2 was essential for initiating this sustained arrest, however, as destruction of Mad2-AID-YFP prior to mitotic entry (in the presence of nocodazole) (legend continued on next page) lead to rapid mitotic exit ( Figures S5B and S5C ). By contrast, IAAinduced destruction of GFP-AID-BubR1 not only disrupted the extended mitotic arrest, but provoked mitotic exit before BubR1 was completely degraded (Figure 5F , red). Taken together, as was seen in our in vitro observations (Figure 4 ), these efforts demonstrate that under conditions in which disassembly of mitotic checkpoint complexes is dampened (by depletion of p31 comet ), BubR1, not Mad2, is required to sustain inhibition of APC/C Cdc20 . We further tested (in an in vivo context) (schematic in Figure 6C ) this model in which Mad2 and BubR1 play discrete roles as a catalytic loader and an effector for Cdc20 inhibition, respectively, with the accelerating rate of APC/C Cdc20 inhibition in vitro reflecting Mad2 dissociation from Cdc20 in a conformation that can rebind another molecule of Cdc20. To do this, cells were first depleted by 90% for either BubR1 or Mad2 using siRNAs (Figure 6D ). To stabilize accumulated Cdc20 inhibitor(s), transfection of siRNA was used to codeplete p31 comet . Nocodazole was added to sustain activation of the mitotic checkpoint, and a 26S proteasome inhibitor was added to inhibit cyclin B destruction, thereby allowing the accumulation of mitotic checkpoint inhibitor(s). After 2 hr, the proteasome inhibitor was removed, and the duration of remaining mitotic arrest was determined by time-lapse microscopy.
Mad2 Acts Catalytically to
In cells with normal levels of Mad2, but with 10% of the normal BubR1 level, washout of the proteasome inhibitor yielded mitotic exit, with >60% of cells exiting mitosis within 4 hr (Figure 6E , blue solid line). By contrast, cells in which Mad2 levels were reduced to 10% of the normal level sustained a mitotic arrest for 16 hr after washout of the proteasome inhibitor (Figure 6E, red solid line) . The normal cellular stoichiometries of BubR1 and Cdc20 have been determined to be 1:1, with Mad2 between 1.3- (Tang et al., 2001 ) and 3-fold (Nilsson et al., 2008) higher. Thus, a 90% depletion of Mad2 reduces it to a level between 13% and 30% of that of Cdc20. Nevertheless, our evidence demonstrates that this limited level of Mad2 can sustain long-term checkpoint signaling if a sufficient time window is provided to allow a BubR1-containing mitotic checkpoint inhibitor to accumulate, consistent with a model in which Mad2 acts catalytically to load BubR1 onto Cdc20.
Mad2
Binding Induces a Functional Switch in Cdc20, Enabling BubR1 Binding Our finding that APC/C-bound Cdc20 association with BubR1 N is significantly enhanced by its prior binding to Mad2 ( Figures  2D and S2F ), along with a previous yeast two-hybrid study (Davenport et al., 2006 ), suggested a model in which the BubR1 binding site within the C-terminal WD40 repeats of Cdc20 may be initially inaccessible as the result of self-association of the Cdc20 amino-and carboxy-terminal domains. To test this directly, we expressed and purified Cdc20 1-163 (hereafter called Cdc20 N ) and GST-Cdc20 166-499 (to be referred to as GST-Cdc20 C ) ( Figures 7A and 7B ). After mixing Cdc20 N and Cdc20 C , followed by purification by glutathione affinity, GST-Cdc20 C , but not GST, copurified Cdc20 N ( Figure 7C ), demonstrating a direct association between the two domains. Moreover, preincubation of Cdc20 N with Cdc20 C reduced subsequent Cdc20 C association with BubR1 N ( Figure 7D ), consistent with blocking BubR1 binding through an intramolecular interaction between two domains in Cdc20 FL . Further, addition of wild-type Mad2, but not the Cdc20-binding defective Mad2 DC , to GST-Cdc20 N and Cdc20 C reduced association of the two Cdc20 domains ( Figure 7E ). Most importantly, while BubR1 N did not bind to Cdc20 FL , Mad2 addition enabled this interaction, producing BubR1 N -Cdc20 FL -Mad2 complexes ( Figure 7F ). By contrast, BubR1 N bound Cdc20 
DISCUSSION
The initiating feature of the checkpoint signaling pathway is a catalytic step at unattached kinetochores where immobilized heterodimers of Mad1-Mad2 act to catalyze a conformational change in inactive Mad2, producing an activated closed form (Kulukian et al., 2009) . To this, our findings here have identified the mitotic checkpoint inhibitor to be produced by synergistic cooperation between Mad2 and BubR1. Mad2 binding reduces the affinity of the amino-and carboxy-terminal Cdc20 domains for each other, exposing a previously poorly accessible BubR1 binding site for Cdc20. This Mad2-dependent functional priming in Cdc20 is essential for BubR1's N terminus to produce the BubR1-Cdc20 mitotic checkpoint inhibitor (Figures 7C-7F ; (E and F) Time-lapse microscopy was used to determine the duration of mitosis in nocodazole (100 ng/ml)-treated cells after (1) depletion of endogenous (E) Mad2 (blue) or (F) BubR1 (blue), (2) replacement of endogenous Mad2 or BubR1 with (E) Mad2-AID-YFP (green) or (F) GFP-AID-BubR1 (green), and (3) induced destruction of (E) Mad2-AID-YFP (red) or (F) GFP-AID-BubR1 (red). Cells were treated with nocodazole prior to filming to facilitate accumulation of the mitotic checkpoint inhibitor(s). More than 60 cells were analyzed for each condition over three independent experiments. See also Figure S5 . modeled in Figure 7G ). BubR1 binding to Cdc20 has a key feature required in a bona fide anaphase inhibitor: the ability to inhibit activated APC/C Cdc20 . Added to this, an affinity of Mad2, in a closed conformation, for BubR1 (Tipton et al., 2011) or Mad3 (Chao et al., 2012) could facilitate BubR1 recruitment to kinetochore-produced Mad2-Cdc20.
Our model for BubR1 bound to Cdc20 as the true mitotic checkpoint-derived inhibitor that blocks APC/C recognition of cyclin B is well supported by (1) the in vitro production of a Mad2-dependent inhibitory APC/C Cdc20 -BubR1-Bub3 complex containing little Mad2 (Kulukian et al., 2009) , (2) (C) Schematic of the protocol used to reduce endogenous p31 comet and Mad2 or BubR1 levels by siRNA transfection, followed by inhibition and release with the 26S proteasome inhibitor (with 25 nM Velcade) and microtubule inhibitor nocodazole (100 ng/ml) so as to provide a temporal delay in mitotic exit and allow accumulation of mitotic checkpoint inhibitor(s), respectively. (D) Levels of depletion of p31 comet , Mad2, or BubR1 by siRNA transfection. (E) Duration of mitosis determined by time-lapse microscopy for cells treated as in (B). Filming began after removal of Velcade and release into nocodaozle. Cells counted in Set A entered mitosis in the presence of both nocodazole and proteasome inhibition, whereas only cells that entered mitosis after removal of the proteasome inhibitor were included in Set B. More than 65 cells were analyzed for each condition. (C) GST-Cdc20 C or GST was affinity purified after incubation with Cdc20 N for 1 hr at room temperature. GST proteins and associated Cdc20 C were analyzed by immunoblotting.
(D) GST-Cdc20 C or GST was incubated with Cdc20 N for 1 hr and then further incubated with BubR1 1-363 for 20 min at room temperature before affinity purification. Associated proteins were analyzed by immunoblotting.
(legend continued on next page)
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Mad2 Catalytically Produces BubR1-Cdc20 Inhibitor depleted of most Mad2 (our evidence), (3) continued inhibition of APC/C Cdc20 in mitotically arrested cells following in vivo targeted destruction of Mad2 (our evidence), and (4) the purification of a stable BubR1-Bub3-Cdc20 complex (free or APC/C bound) containing little Mad2 from cells under chronic mitotic checkpoint arrest (Kulukian et al., 2009; Nilsson et al., 2008) . This model is also supported by prior work that has consistently shown Mad2 to have little ability to inhibit Cdc20 activation of APC/C at physiologically relevant concentrations (Fang, 2002; Kulukian et al., 2009; Sudakin et al., 2001) . Perhaps most importantly, we have shown that Mad2 released from the final inhibitory BubR1-Cdc20 complex can act catalytically to facilitate the loading of additional BubR1 molecules into inhibitory complexes with Cdc20 ( Figure 6 ). We propose that this previously unappreciated catalytic step provides a means to cytosolically amplify initial kinetochore-derived Mad2-Cdc20 mitotic checkpoint complexes ( Figure 7G ), thereby allowing a single unattached kinetochore to globally inhibit APC/C Cdc20 activity. This model contrasts (in a crucial way) with a previous model that had proposed that cytosolic Cdc20-Mad2 complexes would amplify the number of Cdc20-Mad2 complexes, with each such complex acting in turn as an additional structural template to promote the conversion of additional open Mad2 molecules into a closed form that bound and inactivated Cdc20 (De Antoni et al., 2005 ). This latter model had been challenged (Doncic et al., 2005; Mariani et al., 2012) , including on the grounds that, once initiated, the proposed amplification loop (amplifying the number of activated Mad2 molecules, just as the kinetochore does) would obligatorily continue independently of the kinetochore-derived signal and could not be silenced following attachment of the kinetochores to spindle microtubules. Our model, on the other hand, remains responsive to kinetochore-derived signaling and does not amplify the number of catalysts (i.e., activated, closed Mad2); instead, kinetochorederived closed Mad2 is reused for two or more cycles, thereby providing an elevated number of APC/C Cdc20 inhibited by bound BubR1. Finally, rather than being a stable component of the APC/C Cdc20 inhibitory complex, Mad2 0 s continued association with APC/C Cdc20 -BubR1-Bub3 may instead contribute to the pathway of mitotic checkpoint silencing, where p31 comet has been proposed to facilitate dissociation of Mad2 and/or BubR1 from Cdc20 (Chao et al., 2012; Jia et al., 2011; Reddy et al., 2007; Teichner et al., 2011; Westhorpe et al., 2011) or destabilize Cdc20 bound to BubR1 and/or Mad2 (Varetti et al., 2011) . Since our results have established that Mad2 dissociation from Cdc20 leaves a stable BubR1-Cdc20 interaction that continues to inhibit Cdc20 even after Mad2 release (Figures 3 and 4) , our evidence makes it highly unlikely that Mad2 extraction from the inhibitory Mad2-BubR1-Bub3-Cdc20 complex by p31 comet is a key step for checkpoint silencing. Instead, it is BubR1 dissociation from Cdc20 that is critical to reactivate APC/C Cdc20 for cyclin B recognition. While many aspects of mitotic checkpoint inactivation and p31 comet activity remain unresolved, we note that release from APC/C Cdc20 inhibition could be achieved by stimulating deacetylation-derived BubR1 degradation (Choi et al., 2009) or action of some checkpoint protein(s) (including p31 comet ) stimulating Cdc20 degradation (Nilsson et al., 2008; Varetti et al., 2011) , thereby facilitating the generation of active APC/C upon binding of newly synthesized Cdc20.
EXPERIMENTAL PROCEDURES Constructs
Full-length and fragments of the human BubR1 open reading frame were cloned into either a pcDNA5/FRT/TO-based vector (Invitrogen) modified to contain an amino-terminal Myc-LAP epitope tag for mammalian cell expression or a pFastBac1-based vector (Invitrogen) modified to contain an amino-terminal GST-HRV 3C site for insect cell expression. The LAP tag consists of GFP-HRV 3C-63His BubR1 HRV , and Mad2 HRV mutants were generated using PCR-based site-directed mutagenesis to insert a HRV 3C site (LEVLFQGP) (QuikChange, Stratagene). For tetracycline-inducible expression of GFP-AID-BubR1 and Mad2-AID-YFP, the corresponding genes were cloned into a pcDNA5/FRT/TO-based vector (Invitrogen). All other DNA constructs were previously described (Kulukian et al., 2009; Tang et al., 2001 ).
Generation of Stable Cell Lines and siRNA Treatment
Parental Flp-In T-REx-HeLa parental cells that stably express monomeric red fluorescent protein (mRFP)-tagged histone H2B (H2B-mRFP) were as previously described (Gassmann et al., 2010) . Stable, isogenic cell lines expressing MycGFP-BubR1 were generated using FRT/Flp-mediated recombination (Tighe et al., 2004) . Expression of MycGFP-BubR1 was induced with 1 mg/ml tetracycline. siRNA directed against the 3 0 untranslated region of BubR1
(5 0 -CUGUAUGUGCUGUAAUUUA-3 0 ; Figures 1 and 6) or GAPDH (5 0 -UGGUU UACAUGAUCC-AAUA-3 0 ) was purchased from Thermo Fisher Scientific. Cells were transfected with 50 nM of oligonucleotides using Lipofectamine RNAiMAX (Invitrogen). At 14 hr after transfection, tetracycline was added to express MycGFP-BubR1 for 24 hr before collecting cells for immunoblotting or analyzing by time-lapse microscopy. For IAA-inducible protein destruction, TIR1-TIR9Myc was introduced into Flp-In T-REx-DLD-1 parental cells (a kind gift from Stephen Taylor) using retroviral delivery (Shah et al., 2004) . Stable integrates were selected in 2 mg/ml puromycin, and single clones were isolated using single-cell sorting (FACSVantage; Becton Dickinson). Stable, isogenic cell lines expressing Mad2-AID-YFP or GFP-AID-BubR1 were generated using the FRT/Flp-mediated recombination and transgenes induced with tetracycline. To induce protein destruction, cells were treated with 500 mM of IAA. (E) GST-Cdc20 N or GST was incubated with Cdc20 C for 1 hr at room temperature in the presence of Mad2 WT or Mad2
DC
. Associated Mad2 or Cdc20 C was analyzed by immunoblotting.
(F) GST-BubR1 N or GST was affinity purified after incubation with Cdc20 FL or Cdc20 C that had been preincubated with Mad2 or buffer and analyzed for . Following loading of BubR1 onto Cdc20, Mad2 dissociates in a partially active closed conformation (C-Mad2*), which then either binds another free Cdc20 molecule to produce the BubR1-Cdc20 inhibitor (second catalytic step) or converts back to O-Mad2 and is used again in kinetochore signaling (first catalytic step). Thus, one Mad2 molecule produces multiple BubR1-Cdc20 inhibitors through two interlocking catalytic steps.
Live-Cell Microscopy
To determine mitotic timing, cells were seeded onto poly-L-lysine-coated coverglass chamber slides (Thermo Scientific) or poly-L-lysine-coated 35 mm glass-bottomed tissue culture dishes (MatTek) and transferred to supplemented CO 2 -independent media (Invitrogen) 38-48 hr posttransfection. Cells were maintained at 37 C in an environmental control station, and images were collected using a DeltaVision RT System (Applied Precision) with a 403 1.35 numerical aperture (NA) oil lens at 5 min time intervals. For each time point, 6 3 3 mM z sections were acquired for RFP, and maximum intensity projection was created using softWoRx. Movies were assembled and analyzed using QuickTime (Apple) or ImageJ software.
Protein Purification GST-or His-tagged human BubR1, Bub3, and Cdc20 were expressed in Sf9 and High Five insect cells using the Bac-to-Bac expression system (Invitrogen) and affinity purified over nickel-nitrilotriacetic acid beads (QIAGEN) or glutathione sepharose beads (GE Healthcare). His-Mad2 1-102 and other GSTtagged proteins were expressed from Rosetta E.coli after induction with IPTG and then purified (Kulukian et al., 2009) . APC/C was immunoprecipitated from interphase Xenopus egg extracts as previously described (Kulukian et al., 2009) .
APC/C Ubiquitination Activity Assay
The APC/C ubiquitination activity assay was performed as previously described , and activity was assessed by ubiquitinationderived depletion of cyclin B 1-102 substrate (Tugendreich et al., 1995) . Quantitative analysis of cyclin B 1-102 depletion was performed as previously described (Kulukian et al., 2009) . Briefly, the level of cyclin B 1-102 was determined against a series of dilutions of the proteins.
APC/C Binding Assay APC/C was immunoprecipitated from Xenopus interphase egg extracts for 2 hr at 4 C using a peptide-derived anti-Cdc27 antibody crosslinked to Affi-Prep protein A (Bio-Rad) beads. The APC/C beads were washed with Tris-buffered saline (TBS) supplemented with 0.4 M KCl and 0.1% Triton X-100 and incubated with Cdc20 and checkpoint proteins sequentially or simultaneously for the indicated time at room temperature. Unbound proteins were removed by washing the beads twice with 20 volumes of TBS buffer. APC/C complex was eluted from the beads by Cdc27 peptide competition as described (Herzog and Peters, 2005) and analyzed by immunoblotting.
In Vitro Binding Assay
In vitro binding assays were conducted in 50 mM Tris-HCl (pH 7.7), 100 mM KCl, 0.1% Triton X-100, 10% glycerol, and 1 mM DTT. Glutathione Sepharose-bound glutathione S-transferase (GST)-tagged protein and other recombinant proteins were combined and incubated at room temperature for 1 hr. Bound protein complexes were washed four times with 20 volumes of the binding buffer, eluted from the beads in 15 mM glutathione buffer, and analyzed by immunoblotting.
Antibodies
The antibodies used in this study are as follows: BubR1 (SBR1.1, a gift from S. Taylor; A300-386, Bethyl Laboratories), Bub3 (SB3.2, a gift from S. Taylor), Mad1 (BB3-8, a gift from A. Musacchio), Mad2 (A300-300A, Bethyl Laboratories), Cdc20 (A301-180A, Bethyl Laboratories), p31 comet (SC-134381, Santa
Cruz Biotechnology), Millipore) , Cdc27 (Herzog and Peters, 2005) , a-tubulin (DM1a, Sigma-Aldrich), His (A00186, GenScript), and GST (SC-33613, Santa Cruz Biotechnology).
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